FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q58912037> ?p ?o ?g. }

• Q58912037 description "2015 թվականի հունիսի 12-ին հրատարակված գիտական հոդված" @default.
• Q58912037 description "article scientifique publié en 2015" @default.
• Q58912037 description "artículu científicu espublizáu en xunu de 2015" @default.
• Q58912037 description "scientific article published on 12 June 2015" @default.
• Q58912037 description "wetenschappelijk artikel" @default.
• Q58912037 description "наукова стаття, опублікована в червні 2015" @default.
• Q58912037 name "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 name "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 type Item @default.
• Q58912037 label "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 label "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 prefLabel "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 prefLabel "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 P1433 Q58912037-E1E78C9C-FAF5-4869-80C5-B9DF917E419B @default.
• Q58912037 P1476 Q58912037-84C67F1B-43CE-4571-9A0F-4B313F23C2A2 @default.
• Q58912037 P2093 Q58912037-18D3B27F-B324-472D-A46E-85F1C6A163CE @default.
• Q58912037 P2093 Q58912037-2FC9A62F-5BB0-49FD-9383-FBFC908165D4 @default.
• Q58912037 P2093 Q58912037-74866121-9A3F-4300-A686-382A3CC77F2D @default.
• Q58912037 P2093 Q58912037-8253BA48-F8E9-4F62-8193-FC843CE28D32 @default.
• Q58912037 P2093 Q58912037-E2857266-329F-4917-9F2A-91A6E5BFC90E @default.
• Q58912037 P2093 Q58912037-E382EC78-E277-4F55-8C19-95DB60D9F9A4 @default.
• Q58912037 P2093 Q58912037-F6DA3BC8-EA84-47FB-9C2D-7ECA896E8BDB @default.
• Q58912037 P2860 Q58912037-0770592A-8A3D-455A-94C2-BF9200DF7333 @default.
• Q58912037 P2860 Q58912037-0787E730-692B-4095-9D30-C948B596F6EC @default.
• Q58912037 P2860 Q58912037-0D6D0835-9FB8-4E32-AF67-39F255C4676E @default.
• Q58912037 P2860 Q58912037-11399505-3237-4C38-96BD-0EB5A0897B0B @default.
• Q58912037 P2860 Q58912037-191DC8A2-39DE-412E-8DF5-4E2816A653C7 @default.
• Q58912037 P2860 Q58912037-1DEF320C-E3DB-414A-A6CA-78DCC863B957 @default.
• Q58912037 P2860 Q58912037-1FFB5AA3-1DD4-4C05-8F95-F18222E0C864 @default.
• Q58912037 P2860 Q58912037-28A07997-479A-4934-9BEC-96EBC1604B5F @default.
• Q58912037 P2860 Q58912037-32A9D7D1-3096-4005-8FF4-54B9F1EDE6E9 @default.
• Q58912037 P2860 Q58912037-38657BC8-1FDB-4DB5-ABC5-C2AF5128CC16 @default.
• Q58912037 P2860 Q58912037-53900244-A551-4BD9-B924-91E8D73B384B @default.
• Q58912037 P2860 Q58912037-572B0620-B33C-42F0-964E-A140957CB57F @default.
• Q58912037 P2860 Q58912037-6477739F-EE07-4354-A8DC-3E0D46DE292E @default.
• Q58912037 P2860 Q58912037-64C3D73D-D4D4-4DC0-8E5F-B183A2839EDC @default.
• Q58912037 P2860 Q58912037-6D365C9F-01A6-4A11-B668-28E72E69CD4A @default.
• Q58912037 P2860 Q58912037-756B8B01-3775-46EC-B166-D3EBD3B9DF61 @default.
• Q58912037 P2860 Q58912037-75DF02BA-59BC-4794-B721-CC0355067DE9 @default.
• Q58912037 P2860 Q58912037-7B8D4490-6925-416C-A829-4CCD52D770A9 @default.
• Q58912037 P2860 Q58912037-81BF2435-CD1B-4822-8DE8-B2A6D6615B35 @default.
• Q58912037 P2860 Q58912037-8B3B5EBB-9D34-4FFD-BC32-0E658828B78F @default.
• Q58912037 P2860 Q58912037-A3D560D4-67F3-4509-83BA-314381901864 @default.
• Q58912037 P2860 Q58912037-A7A0F12D-62EF-4D3F-B3E9-CD12B02EFB3C @default.
• Q58912037 P2860 Q58912037-A8298700-3177-4E4A-AD38-F57B8046D8A6 @default.
• Q58912037 P2860 Q58912037-A95EDE0E-6171-4248-A91A-C4A056712062 @default.
• Q58912037 P2860 Q58912037-BA03BEDD-8A65-4D29-B17D-75AEBAC90DEC @default.
• Q58912037 P2860 Q58912037-C078633E-FD72-4623-AE56-64084603C042 @default.
• Q58912037 P2860 Q58912037-D1E99D21-EE7C-462F-A4F9-C9523BF04971 @default.
• Q58912037 P2860 Q58912037-D423E1F3-5BAD-4683-AD72-C40561A5D07A @default.
• Q58912037 P2860 Q58912037-DE9FAF23-24C5-4EB6-9404-8403E6224D85 @default.
• Q58912037 P2860 Q58912037-DF9F4382-97C2-4CF0-939F-DA9DCEE4FD2D @default.
• Q58912037 P2860 Q58912037-E1E70A85-19B4-4372-87B7-9A520FBA29B8 @default.
• Q58912037 P2860 Q58912037-E7D832AC-8A22-42EE-9C26-C66AAF2802D8 @default.
• Q58912037 P2860 Q58912037-F3F06B96-49A1-43AA-87BF-663D70E9D92B @default.
• Q58912037 P2860 Q58912037-F5445816-F168-4337-9665-436F62A86424 @default.
• Q58912037 P2860 Q58912037-F7C7C8F0-97D8-412A-8B6E-367E31D99609 @default.
• Q58912037 P2860 Q58912037-F92499A3-3F68-4498-B459-CAD0AAD66E85 @default.
• Q58912037 P304 Q58912037-92122735-3722-4FB5-82F1-5ECD4463A741 @default.
• Q58912037 P31 Q58912037-BBA1FFA0-D04F-4AE5-B350-CC3EEB4D45BF @default.
• Q58912037 P356 Q58912037-2A98DB55-EF4F-46FB-9A03-86E187D99902 @default.
• Q58912037 P433 Q58912037-A357DA7A-29A2-42F2-9827-B8531FBB1AAB @default.
• Q58912037 P478 Q58912037-BDB51DAC-29FB-43F0-941E-8EE545EB6AB8 @default.
• Q58912037 P50 Q58912037-2F279786-A51A-48F2-A22C-A4A1CC93CB45 @default.
• Q58912037 P577 Q58912037-F43703BB-7497-4C38-9762-CF3354C4FE00 @default.
• Q58912037 P698 Q58912037-3F663323-9976-4460-BCAC-B96772594780 @default.
• Q58912037 P921 Q58912037-22e706a5-06f5-49f7-9cce-dce23f70066c @default.
• Q58912037 P921 Q58912037-2E4AC7B9-3BF7-407C-BFFC-43DB4C2AD5CF @default.
• Q58912037 P921 Q58912037-61b96232-0c8d-45d6-be17-50111d48c47f @default.
• Q58912037 P921 Q58912037-DFB5D902-D76F-4CE4-9110-862F57C950BE @default.
• Q58912037 P921 Q58912037-fa2e8ae3-9dfe-4ca5-adb9-3d97460b6a24 @default.
• Q58912037 P356 PAPR.12308 @default.
• Q58912037 P698 26095455 @default.
• Q58912037 P1433 Q2183039 @default.
• Q58912037 P1476 "Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study" @default.
• Q58912037 P2093 "Dietmar Falke" @default.
• Q58912037 P2093 "Francisco J Blanco" @default.
• Q58912037 P2093 "Ilona Steigerwald" @default.
• Q58912037 P2093 "Lieven Kennes" @default.
• Q58912037 P2093 "Matthias Müller" @default.
• Q58912037 P2093 "Ralf Baron" @default.
• Q58912037 P2093 "Rudolf Likar" @default.
• Q58912037 P2860 Q24616897 @default.
• Q58912037 P2860 Q24805041 @default.
• Q58912037 P2860 Q28209970 @default.
• Q58912037 P2860 Q28248823 @default.
• Q58912037 P2860 Q29394898 @default.
• Q58912037 P2860 Q33748032 @default.
• Q58912037 P2860 Q33775071 @default.
• Q58912037 P2860 Q34620698 @default.
• Q58912037 P2860 Q34625849 @default.
• Q58912037 P2860 Q34636895 @default.
• Q58912037 P2860 Q34691911 @default.
• Q58912037 P2860 Q35751708 @default.
• Q58912037 P2860 Q35994723 @default.
• Q58912037 P2860 Q37031540 @default.
• Q58912037 P2860 Q37115472 @default.
• Q58912037 P2860 Q37237096 @default.
• Q58912037 P2860 Q37401775 @default.
• Q58912037 P2860 Q37419508 @default.

• next